Linked e-resources
Details
Table of Contents
Preface; References; Contents; Part I: Definition, Epidemiology, and Pathogenesis; Chapter 1: Definition of IPF; 1.1 Introduction; 1.2 The ATS/ERS/JRS/ALAT 2011 Revised Diagnostic Criteria [5]; 1.3 Clinical Application and Key Problems; 1.4 Conclusion; References; Chapter 2: Epidemiology and Risk Factors of IPF; 2.1 Introduction; 2.2 Incidence and Prevalence; 2.2.1 In the USA; 2.2.2 In Europe; 2.2.3 In Japan; 2.3 Potential Risk Factors; 2.3.1 Smoking; 2.3.2 Inhalational Exposures; 2.3.3 Viral Infection; 2.3.4 Herpesviruses; 2.3.5 Hepatitis C Virus; 2.3.6 Gastroesophageal Reflux
2.3.7 Diabetes Mellitus2.4 Genetic Factors; 2.4.1 Familial Interstitial Pneumonia (FIP); 2.4.2 ELMOD2; 2.4.3 Surfactant Protein; 2.4.4 Telomerase; 2.4.5 MUC5B; 2.5 Conclusions; References; Chapter 3: Acute Exacerbation of IPF; 3.1 Introduction; 3.2 Definition; 3.3 Pathophysiology; 3.4 Trigger Factors; 3.5 Epidemiology; 3.6 Histopathology; 3.7 Radiological Assessment; 3.8 Laboratory Tests and Biomarkers; 3.9 Pharmacological Treatments; 3.10 Therapy with Polymyxin B-Immobilized Fiber Column; 3.11 Prevention; 3.12 Conclusions; References; Chapter 4: Pathogenesis of IPF
4.1 Hypothesis of the Molecular Pathogenesis of IPF: From Inflammation to Epithelial Injury4.2 Epithelial Injury and Genetic Background; 4.3 Biological Alteration in Injured AEC in IPF; 4.4 Critical Roles of Growth Factors in the Progression of Pulmonary Fibrosis; 4.4.1 PDGF and PDGF Receptors; 4.4.2 FGF and FGF Receptors; 4.4.3 VEGF and VEGF Receptors; 4.4.4 TGF-beta and TGF-beta Receptors; 4.4.5 Origin of Lung Fibroblasts and Their Contribution to Pulmonary Fibrosis; 4.4.6 Loss of Alveolar Epithelial Integrity and Pulmonary Fibrosis; 4.4.7 Resolution of ECM and Fibrosis; 4.4.8 Conclusions
5.7 Relation Between HRCT Findings and Biomarkers5.8 Mechanism and Significance for Dissociation Among Serum Biomarker Levels; 5.9 Biomarkers for IPF Other Than SP-A, SP-D, and KL-6; 5.10 Conclusion; References; Chapter 6: High-Resolution Computed Tomography of Honeycombing and IPF/UIP; 6.1 Introduction; 6.2 Honeycomb Lung (Honeycombing); 6.2.1 Definition of Honeycomb Lung; 6.2.2 Disagreement Among Radiologists in Judging Honeycomb Lung; 6.3 Imaging Findings of Idiopathic Pulmonary Fibrosis/Usual Interstitial Pneumonia; 6.3.1 Pathologic Criteria of IPF/UIP; 6.3.2 HRCT Criteria of IPF/UIP
2.3.7 Diabetes Mellitus2.4 Genetic Factors; 2.4.1 Familial Interstitial Pneumonia (FIP); 2.4.2 ELMOD2; 2.4.3 Surfactant Protein; 2.4.4 Telomerase; 2.4.5 MUC5B; 2.5 Conclusions; References; Chapter 3: Acute Exacerbation of IPF; 3.1 Introduction; 3.2 Definition; 3.3 Pathophysiology; 3.4 Trigger Factors; 3.5 Epidemiology; 3.6 Histopathology; 3.7 Radiological Assessment; 3.8 Laboratory Tests and Biomarkers; 3.9 Pharmacological Treatments; 3.10 Therapy with Polymyxin B-Immobilized Fiber Column; 3.11 Prevention; 3.12 Conclusions; References; Chapter 4: Pathogenesis of IPF
4.1 Hypothesis of the Molecular Pathogenesis of IPF: From Inflammation to Epithelial Injury4.2 Epithelial Injury and Genetic Background; 4.3 Biological Alteration in Injured AEC in IPF; 4.4 Critical Roles of Growth Factors in the Progression of Pulmonary Fibrosis; 4.4.1 PDGF and PDGF Receptors; 4.4.2 FGF and FGF Receptors; 4.4.3 VEGF and VEGF Receptors; 4.4.4 TGF-beta and TGF-beta Receptors; 4.4.5 Origin of Lung Fibroblasts and Their Contribution to Pulmonary Fibrosis; 4.4.6 Loss of Alveolar Epithelial Integrity and Pulmonary Fibrosis; 4.4.7 Resolution of ECM and Fibrosis; 4.4.8 Conclusions
5.7 Relation Between HRCT Findings and Biomarkers5.8 Mechanism and Significance for Dissociation Among Serum Biomarker Levels; 5.9 Biomarkers for IPF Other Than SP-A, SP-D, and KL-6; 5.10 Conclusion; References; Chapter 6: High-Resolution Computed Tomography of Honeycombing and IPF/UIP; 6.1 Introduction; 6.2 Honeycomb Lung (Honeycombing); 6.2.1 Definition of Honeycomb Lung; 6.2.2 Disagreement Among Radiologists in Judging Honeycomb Lung; 6.3 Imaging Findings of Idiopathic Pulmonary Fibrosis/Usual Interstitial Pneumonia; 6.3.1 Pathologic Criteria of IPF/UIP; 6.3.2 HRCT Criteria of IPF/UIP